首药控股(688197) - 2025 Q4 - 年度业绩

Financial Performance - The total revenue for 2025 reached RMB 8.67 million, a year-on-year increase of 119.88%[4] - The net loss attributable to the parent company was RMB 128.83 million, an improvement from a loss of RMB 211.94 million in the previous year[5] - The company’s total assets at the end of the reporting period were RMB 791.23 million, down 14.20% from the beginning of the period[4] - The equity attributable to the parent company decreased by 15.92% to RMB 680.18 million[4] - The basic earnings per share improved to -RMB 0.87 from -RMB 1.43 in the previous year[4] Government Support - The company received government subsidies totaling RMB 60.76 million during the reporting period, contributing to the reduction in operating losses[8] Drug Development - The NDA for SY-707 is progressing steadily, with submission to the CDE completed in November 2025[5] - The NDA for SY-5007 was accepted in October 2025, with key clinical trial results presented at the ESMO annual meeting[5] - The company is focusing on the development of small molecule tumor drugs and expanding its clinical pipeline[5] - The company aims to enhance its drug development pipeline by pushing more candidate drugs into clinical trials[7]